Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Intranasal BMP9 Ameliorates Alzheimer Disease-Like Pathology and Cognitive Deficits in APP/PS1 Transgenic Mice.

Wang Z, Xiong L, Wan W, Duan L, Bai X, Zu H.

Front Mol Neurosci. 2017 Feb 8;10:32. doi: 10.3389/fnmol.2017.00032. eCollection 2017.

2.

Icariside II, a Broad-Spectrum Anti-cancer Agent, Reverses Beta-Amyloid-Induced Cognitive Impairment through Reducing Inflammation and Apoptosis in Rats.

Deng Y, Long L, Wang K, Zhou J, Zeng L, He L, Gong Q.

Front Pharmacol. 2017 Feb 2;8:39. doi: 10.3389/fphar.2017.00039. eCollection 2017.

3.

Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation.

Moore AH, Bigbee MJ, Boynton GE, Wakeham CM, Rosenheim HM, Staral CJ, Morrissey JL, Hund AK.

Pharmaceuticals (Basel). 2010 Jun 2;3(6):1812-1841. Review.

4.

Glucose levels during life and neuropathologic findings at autopsy among people never treated for diabetes.

Crane PK, Walker RL, Sonnen J, Gibbons LE, Melrose R, Hassenstab J, Keene CD, Postupna N, Montine TJ, Larson EB.

Neurobiol Aging. 2016 Dec;48:72-82. doi: 10.1016/j.neurobiolaging.2016.07.021. Epub 2016 Aug 1.

PMID:
27644076
5.

Shared genetic contribution to Ischaemic Stroke and Alzheimer's Disease.

Traylor M, Adib-Samii P, Harold D; Alzheimer's Disease Neuroimaging Initiative; International Stroke Genetics Consortium (ISGC), UK Young Lacunar Stroke DNA resource, Dichgans M, Williams J, Lewis CM, Markus HS; METASTROKE; International Genomics of Alzheimer's Project (IGAP), investigators.

Ann Neurol. 2016 Feb 23. doi: 10.1002/ana.24621. [Epub ahead of print]

6.

Bridging the Translation Gap: From Dementia Risk Assessment to Advice on Risk Reduction.

Anstey KJ, Eramudugolla R, Hosking DE, Lautenschlager NT, Dixon RA.

J Prev Alzheimers Dis. 2015;2(3):189-198.

7.

Prescription Opioids and Risk of Dementia or Cognitive Decline: A Prospective Cohort Study.

Dublin S, Walker RL, Gray SL, Hubbard RA, Anderson ML, Yu O, Crane PK, Larson EB.

J Am Geriatr Soc. 2015 Aug;63(8):1519-26. doi: 10.1111/jgs.13562.

8.

Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer's disease pathology.

Baruch K, Rosenzweig N, Kertser A, Deczkowska A, Sharif AM, Spinrad A, Tsitsou-Kampeli A, Sarel A, Cahalon L, Schwartz M.

Nat Commun. 2015 Aug 18;6:7967. doi: 10.1038/ncomms8967.

9.

Does neuroinflammation turn on the flame in Alzheimer's disease? Focus on astrocytes.

Steardo L Jr, Bronzuoli MR, Iacomino A, Esposito G, Steardo L, Scuderi C.

Front Neurosci. 2015 Jul 29;9:259. doi: 10.3389/fnins.2015.00259. eCollection 2015. Review.

10.

NSAID Use and Incident Cognitive Impairment in a Population-based Cohort.

Wichmann MA, Cruickshanks KJ, Carlsson CM, Chappell R, Fischer ME, Klein BE, Klein R, Schubert CR.

Alzheimer Dis Assoc Disord. 2016 Apr-Jun;30(2):105-12. doi: 10.1097/WAD.0000000000000098.

11.

Acupuncture at the Taixi (KI3) acupoint activates cerebral neurons in elderly patients with mild cognitive impairment.

Chen S, Xu M, Li H, Liang J, Yin L, Liu X, Jia X, Zhu F, Wang D, Shi X, Zhao L.

Neural Regen Res. 2014 Jun 1;9(11):1163-8. doi: 10.4103/1673-5374.135319.

12.

Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging.

Zimmer ER, Leuzy A, Benedet AL, Breitner J, Gauthier S, Rosa-Neto P.

J Neuroinflammation. 2014 Jul 8;11:120. doi: 10.1186/1742-2094-11-120. Review.

13.

Glimepiride reduces CD14 expression and cytokine secretion from macrophages.

Ingham V, Williams A, Bate C.

J Neuroinflammation. 2014 Jun 21;11:115. doi: 10.1186/1742-2094-11-115.

14.

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.

Karran E, Hardy J.

Ann Neurol. 2014 Aug;76(2):185-205. doi: 10.1002/ana.24188. Epub 2014 Jul 2. Review. No abstract available.

15.

Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors.

Shinohara M, Sato N, Shimamura M, Kurinami H, Hamasaki T, Chatterjee A, Rakugi H, Morishita R.

Front Aging Neurosci. 2014 Apr 23;6:71. doi: 10.3389/fnagi.2014.00071. eCollection 2014. Review.

16.

The role of inflammasome in Alzheimer's disease.

Liu L, Chan C.

Ageing Res Rev. 2014 May;15:6-15. doi: 10.1016/j.arr.2013.12.007. Epub 2014 Feb 19. Review.

17.

The Cache County Study on Memory in Aging: factors affecting risk of Alzheimer's disease and its progression after onset.

Tschanz JT, Norton MC, Zandi PP, Lyketsos CG.

Int Rev Psychiatry. 2013 Dec;25(6):673-85. doi: 10.3109/09540261.2013.849663.

18.

Inflammatory process in Alzheimer's Disease.

Meraz-Ríos MA, Toral-Rios D, Franco-Bocanegra D, Villeda-Hernández J, Campos-Peña V.

Front Integr Neurosci. 2013 Aug 13;7:59. doi: 10.3389/fnint.2013.00059. eCollection 2013.

19.

The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease.

Lynch MA.

Immunology. 2014 Mar;141(3):292-301. doi: 10.1111/imm.12156. Review.

20.

Cognitive dysfunction with aging and the role of inflammation.

Simen AA, Bordner KA, Martin MP, Moy LA, Barry LC.

Ther Adv Chronic Dis. 2011 May;2(3):175-95. doi: 10.1177/2040622311399145.

Supplemental Content

Support Center